379 related articles for article (PubMed ID: 25918286)
21. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
Brambilla E; Le Teuff G; Marguet S; Lantuejoul S; Dunant A; Graziano S; Pirker R; Douillard JY; Le Chevalier T; Filipits M; Rosell R; Kratzke R; Popper H; Soria JC; Shepherd FA; Seymour L; Tsao MS
J Clin Oncol; 2016 Apr; 34(11):1223-30. PubMed ID: 26834066
[TBL] [Abstract][Full Text] [Related]
22. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.
Travis WD; Brambilla E; Noguchi M; Nicholson AG; Geisinger KR; Yatabe Y; Beer DG; Powell CA; Riely GJ; Van Schil PE; Garg K; Austin JH; Asamura H; Rusch VW; Hirsch FR; Scagliotti G; Mitsudomi T; Huber RM; Ishikawa Y; Jett J; Sanchez-Cespedes M; Sculier JP; Takahashi T; Tsuboi M; Vansteenkiste J; Wistuba I; Yang PC; Aberle D; Brambilla C; Flieder D; Franklin W; Gazdar A; Gould M; Hasleton P; Henderson D; Johnson B; Johnson D; Kerr K; Kuriyama K; Lee JS; Miller VA; Petersen I; Roggli V; Rosell R; Saijo N; Thunnissen E; Tsao M; Yankelewitz D
J Thorac Oncol; 2011 Feb; 6(2):244-85. PubMed ID: 21252716
[TBL] [Abstract][Full Text] [Related]
23. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma.
Warth A; Muley T; Kossakowski C; Stenzinger A; Schirmacher P; Dienemann H; Weichert W
J Thorac Oncol; 2015 Apr; 10(4):638-44. PubMed ID: 25634008
[TBL] [Abstract][Full Text] [Related]
25. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.
Eguchi T; Kadota K; Park BJ; Travis WD; Jones DR; Adusumilli PS
Semin Thorac Cardiovasc Surg; 2014; 26(3):210-22. PubMed ID: 25527015
[TBL] [Abstract][Full Text] [Related]
26. Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail?
Russell PA; Wright GM
Ann Transl Med; 2016 Jan; 4(1):16. PubMed ID: 26855952
[TBL] [Abstract][Full Text] [Related]
27. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
28. Differential gene expression profiles according to the Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society histopathological classification in lung adenocarcinoma subtypes.
Molina-Romero C; Rangel-Escareño C; Ortega-Gómez A; Alanis-Funes GJ; Avilés-Salas A; Avila-Moreno F; Mercado GE; Cardona AF; Hidalgo-Miranda A; Arrieta O
Hum Pathol; 2017 Aug; 66():188-199. PubMed ID: 28603066
[TBL] [Abstract][Full Text] [Related]
29. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
[TBL] [Abstract][Full Text] [Related]
30. Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.
Ashok Kumar P; Karimi M; Basnet A; Seymour L; Kratzke R; Brambilla E; Le-Chevalier T; Soria JC; Olaussen KA; Devarakonda S; Govindan R; Tsao MS; Shepherd FA; Michiels S; Graziano S
Clin Lung Cancer; 2023 Sep; 24(6):528-540. PubMed ID: 37438216
[TBL] [Abstract][Full Text] [Related]
31. The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Ogata SY; Sato T; Tamura G
Ann Thorac Surg; 2014 Aug; 98(2):453-8. PubMed ID: 24961844
[TBL] [Abstract][Full Text] [Related]
32. Current readings: pathology, prognosis, and lung cancer.
Suh JH
Semin Thorac Cardiovasc Surg; 2013; 25(1):14-21. PubMed ID: 23800525
[TBL] [Abstract][Full Text] [Related]
33. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.
Zhang J; Wu J; Tan Q; Zhu L; Gao W
J Thorac Oncol; 2013 Sep; 8(9):1196-202. PubMed ID: 23945388
[TBL] [Abstract][Full Text] [Related]
34. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
[TBL] [Abstract][Full Text] [Related]
35. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma.
Lu D; Yang J; Liu X; Feng S; Dong X; Shi X; Zhai J; Mai S; Jiang J; Wang Z; Wu H; Cai K
Cancer Med; 2020 May; 9(10):3455-3462. PubMed ID: 32207885
[TBL] [Abstract][Full Text] [Related]
37. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.
Yeh YC; Kadota K; Nitadori J; Sima CS; Rizk NP; Jones DR; Travis WD; Adusumilli PS
Eur J Cardiothorac Surg; 2016 Jan; 49(1):e9-e15. PubMed ID: 26377636
[TBL] [Abstract][Full Text] [Related]
38. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma.
Westaway DD; Toon CW; Farzin M; Sioson L; Watson N; Brady PW; Marshman D; Mathur MM; Gill AJ
Pathology; 2013 Oct; 45(6):553-8. PubMed ID: 24018816
[TBL] [Abstract][Full Text] [Related]
39. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
40. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification.
Russell PA; Wainer Z; Wright GM; Daniels M; Conron M; Williams RA
J Thorac Oncol; 2011 Sep; 6(9):1496-504. PubMed ID: 21642859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
